Dr. Robert (Rob) Yeh advises pharmaceutical and life sciences companies and their investors on intellectual property issues that are essential to their success at all stages of their life cycle.
Rob draws on his extensive experience as a former scientist and patent litigator to guide clients on matters in:
He often represents buyers, sellers, investment banks, and other financial institutions in performing IP due diligence in connection with private and public financings, investments, as well as mergers and acquisitions.
Rob is registered to practice before the US Patent and Trademark Office. Before joining Latham, he developed substantial experience in patent litigation and patent prosecution and counseling, including representing multinational and startup companies in patent matters.
Rob holds a PhD from UC Berkeley in chemistry for his work in Dr. Kenneth Raymond’s laboratory on self-assembled nanoparticle technology. He was a postdoctoral researcher at The Scripps Research Institute where he developed VLPs for drug delivery. He was a research scientist at a multinational medical diagnostics company, where he focused on bioconjugation and macromolecular imaging agents (MRI and PET).
A recognized thought leader in the life sciences IP space, Rob is a named co-inventor on a US patent and a co-author of 10 peer-reviewed scientific publications.
Rob’s recent representative experiences include:
*Matters handled prior to joining Latham
Thought Leadership
Scientific Publications
Latham honored for securing a US$10.75 million damages verdict for client Philip Morris International in a patent infringement trial over vaping technology against R.J. Reynolds Vapor.
Chambers USA recognized the firm’s Mergers & Acquisitions Practice for “world class expertise when it comes to the most challenging transactions.”